Athira Pharma Inc expected to post a loss of 24 cents a share - Earnings Preview

LeonaBio

09/05/2025 12:59

Athira Pharma Inc ATHA.OQ ATHA.O is expected to report results on May 13 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Athira Pharma Inc is for a loss of 24 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Athira Pharma Inc is $0.55​, above​ its last closing price of $0.27. ​​​

This summary was machine generated May 9 at 11:59 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)